Global Website
About Aquablation Therapy
5-Year Clinical Data
Contact Us
Making a Lasting Change to the
BPH Landscape
Elevate Your Expectations in
BPH Surgical Technology
See the Results: 5-Year Clinical Data
Learn More
Previous slide
Next slide

Why are millions of men waiting on the sidelines instead of having benign prostatic hyperplasia (BPH) surgery?

Your patients deserve more.

  • Efficacy Matters
  • Sexual Function Matters
  • Durability Matters
  • Urinary Continence Matters

BPH is a Common and Burdensome Condition

99%
of men say BPH impacts
quality of life1
75%
of men say BPH impacts
self‑esteem1
85%
of men with BPH are concerned that
surgery will cause incontinence1

Did you know that 83% of patients are not willing to sacrifice sexual function for symptom relief with surgery? 1

Men should not have to choose between symptom relief and sexual function.

PROCEPT BioRobotics is Changing the BPH Landscape

PROCEPT BioRobotics was founded on the belief that there must be
a better way to treat BPH.

Aquablation therapy is the first and only ultrasound guided, robotic‑assisted, heat‑free waterjet for the treatment of BPH.

Real-time image guidance

Intraoperative ultrasound imaging combined with cystoscopy enables identification of critical anatomy.

Personalized treatment planning

Computer-assisted planning allows the surgeon to maximize tissue resection while sparing the bladder neck, verumontanum, and external sphincter.

Robotic-assisted waterjet resection

Robotic-assisted execution has been shown to deliver predictable tissue resection in prostates of all sizes and shapes with a heat-free waterjet.

Aquablation therapy is the only BPH treatment that is proven to match TURP’s durability & efficacy while preserving sexual function and continence. 2

Proven Results With

Aquablation Therapy
Clinically proven to provide long-term symptom relief with low rates of irreversible complications on prostates of all shapes and sizes.2,3
Aquablation therapy is the only BPH treatment with 5‑year data from two prospective US Food and Drug Administration (FDA) studies, one of which was a randomized, double‑blinded study versus TURP.2,3

In clinical trials:

16-point

International Prostate Symptom Score (IPSS) improvement showing significant symptom relief 2-4

94%

of patients did not need another BPH intervention at 5 years post‑Aquablation therapy2,3

99%

of patients did not experience incontinence5

100%

of patients preserved
erectile function5

89%

of patients preserved
ejaculatory function5

In prostate sizes 50-80 mL, Aquablation therapy showed superior safety, efficacy, and durability versus TURP.6

5-Year Clinical Results

Level 1 Evidence2

Randomized clinical trial (2:1), double-blinded, 30‑80 mL, n=181

  • Aquablation therapy achieved superiority to TURP for the primary safety endpoint due to low irreversible complications
  • Aquablation therapy non-inferior to TURP for efficacy (IPSS)
  • Aquablation therapy efficacy results maintained through 5‑year follow-up
  • Durability: Aquablation therapy had 51% fewer patients returning to BPH medication or undergoing a secondary BPH intervention compared with TURP

Resulted in Global BPH Guidelines Inclusion

Prospective Cohort Data2,3​

Two unique cohorts with 5-year outcomes

n = 96

Pre-specified subgroup analysis in medium gland sizes

50 – 80 mL
5‑Year Results
  • Superior safety compared to TURP due to low irreversible complications
  • Superior efficacy in IPSS
  • Superior durability due to fewer patients returning to BPH medication or needing a secondary procedure
n = 101

First prospective multicenter study successfully completed for large prostates

80 – 150 mL
5‑Year Results
  • Only treatment for large prostates with a low irreversible complication rate
  • Size independent procedure
  • Significant symptom relief in large prostates

Symptom Relief and Durability Over 5 Years2,3​

Data from 2 FDA prospective trials

IPSS

5-year retreatment due to LUTS

AquaBeam Robotic System

The first and only ultrasound guided, robotic-assisted, heat-free waterjet for the treatment of BPH.

Step 1

Creating a Surgical Map

Play Video

Step 2

Removing the Prostate Tissue

Play Video

Personalized treatment planning combined with robotic precision maximizes tissue resection while protecting areas of the anatomy responsible for erectile and ejaculatory function as well as continence.

Attending AUA?

AUA 2024 PROCEPT BioRobotics Schedule

Aquablation Therapy Hands‑On Workshops

Space is Limited

Friday, May 3

9:00AM – 4:00 PM

Register for this small-group session to experience for yourself why Aquablation therapy continues to disrupt the legacy treatment landscape for men with BPH.

Aquablation therapy is the only ultrasound guided, robotic-assisted, heat-free waterjet for the treatment of BPH.

Workshop Includes:

  • Introduction to PROCEPT and Aquablation therapy
  • Hands-on learning with an Aquablation therapy surgeon
  • Procedure overview and small-group demonstration

Surgeon Hosts:

Lewis Kriteman, MD, FACS
Georgia Urology

David Cuellar, MD
Urology Austin

Christopher E. Kelly, MD
NYU Langone Urology Associates

Appointments available every hour.

Register

Evening Events

Friday, May 3

4:30-6:30 PM
1 Watson–Rooftop Restaurant
111 Soledad St

Join colleagues and PROCEPT executives and learn why over 400,000 potential patients were actively seeking Aquablation therapy on our website in 2023.

RSVP

Saturday, May 4

4:00-6:00 PM | Procept Booth #1429

Join us at the PROCEPT booth during the AUA “Saturday Afternoon Social” and experience our momentum, 15 years in the making.

Surgeon Presentations at Procept Booth #1429

Friday, May 3

12:00 PM | Procept Booth #1429
"From Enucleation (ThuLEP) to Aquablation"
Gerald Park, MD
Kansas City Urology Care

Saturday May 4

12:00 PM | Procept Booth #1429
“Why Aquablation Is My First-Line BPH Treatment: An Expert's Experience After 500 Procedures"
Lewis Kriteman, MD, FACS
Georgia Urology

Saturday May 4

3:00 PM | Procept Booth #1429
"Aquablation Day Case: Experience With Same Calendar Day Outpatient Surgery"
Kevin Zorn, MD, FRCSC, FACS
Steinberg Urology

AUA Posters and Podium Presentations

12 Scientific Abstracts Feature Aquablation Therapy at AUA.

Key topics include:

  • First published experience of same day discharge in an ambulatory surgical center
  • Real-world outcomes

  • Five-year update comparing Aquablation therapy for BPH in 30-80 cc and 80-150 cc prostates

Click here for details on the abstracts

In accordance with the Physician Payment Sunshine Act, PROCEPT BioRobotics is required to report any payments or other transfers of value made to you as part of this program.

Vermont-Licensed HCPs: Vermont laws prohibit this program from providing any food, meals or refreshments at no charge to healthcare professionals licensed by and regularly practicing in Vermont. Physicians licensed in Vermont will need to purchase their own food, meals, or refreshments to participate in this program.

Not able to attend?

Speak with a local representative.
Request more information
Accordion Content

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

As with any surgical urologic procedure, potential perioperative risks of the Aquablation procedure include but are not limited to the following, some of which may lead to serious outcomes and may require intervention:

  • Anesthesia risk
  • Bladder or prostate capsule perforation
  • Bladder neck contracture
  • Bleeding or blood in the urine
  • Bruising
  • Penile or pelvic pain
  • Irritative symptoms, which may include dysuria, urgency or frequency
  • Infection
  • Transurethral resection (TUR) syndrome
  • Electric shock/burn
  • Urethral damage causing false passage or stricture
  • Rectal incontinence / perforation
  • Sexual dysfunction, including ejaculatory and erectile dysfunction
  • Incontinence or overactive bladder
  • Embolism
  • Urinary Retention

 

Rx Only

References

  1. Data on file at PROCEPT BioRobotics.
  2. Gilling PJ et al. Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH. Can J Urol. 2022;29(1):10960-10968.
  3. Bhojani et al. Aquablation therapy in large prostates (80-150 mL) for lower urinary tract symptoms due to benign prostatic hyperplasia: final WATER II 5-Year clinical trial results. 2023 Journal of Urology.
  4. Bach T et al. First multi-center all-comers study for the Aquablation procedure. J Clin Med. 2020;9(2):603.
  5. Elterman D et al. Meta-analysis with individual data of functional outcomes following Aquablation for lower urinary tract symptoms due to BPH in various prostate anatomies. BMJ Surg Interv Health Technol. 2021;3(1):e000090.
  6. Oumedjbeur K et al. Aquablation versus TURP: 5-year outcomes of the WATER randomized clinical trial for prostate volumes 50-80 mL. Can J Urol. 2023;30(5):11650-11658.

 

Please review the Instructions for Use and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions, and potential adverse events.

Intended Use: This product is intended for the resection and removal of prostate tissue in males suffering from lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia.

150 Baytech Drive
San Jose, CA 95134

+1 (650) 232-7200

info@PROCEPT-BioRobotics.com

© 2024 PROCEPT BioRobotics Corporation. All rights reserved. AQUABLATION, AquaBeam, PROCEPT BioRobotics and the PROCEPT BioRobotics logo are the registered trademarks of PROCEPT BioRobotics Corporation, in the United States and other territories. ML0545.A

Attending AUA